Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.56 |
| ▸ | MMP9 | P14780 | 4/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.55 |
| ▸ | ITGA2 | P17301 | 2/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.49 |
| ▸ | ITGAV | P06756 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12084433 | 1.00 | MMP2 (0.56) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL4253026 | 0.92 | ITGB1 (0.62) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL12084566 | 0.92 | ITGB1 (0.62) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL4251535 | 0.87 | ITGB1 (0.73) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL8245510 | 0.87 | ITGB1 (0.73) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL4254786 | 0.86 | ITGB1 (0.56) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL12084471 | 0.86 | ITGB1 (0.56) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL8248905 | 0.85 | ITGB1 (0.58) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL4257956 | 0.85 | ITGB1 (0.58) | MMP2MMP9ITGB1ITGA2ITGA4 | |
| SCHEMBL12017287 | 0.85 | ITGB1 (0.59) | MMP2MMP9ITGB1ITGA2ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258159-B2 | Inhibitors of the α2β1/GPIa-IIa integrin | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-09-04 | — | — | US | claimed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | claimed |
| EP-1898940-A1 | INHIBITORS OF THE ALPHA2BETA 1/GPIA-IIA INTEGRIN | The Trustees of The University of Pennsylvania (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2006133338-A1 | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA (US) | 2006-12-14 | — | — | WO | claimed |
| US-8258159-B2 | Inhibitors of the α2β1/GPIa-IIa integrin | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1898940-A1 | INHIBITORS OF THE ALPHA2BETA 1/GPIA-IIA INTEGRIN | The Trustees of The University of Pennsylvania (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006133338-A1 | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | ITGA2B, ITGB2, ITGA2 | MMP2 695/4885MMP9 800/4885ITGB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.